Skip to main content
Top
Published in: World Journal of Urology 4/2007

01-08-2007 | Original Article

The rationale for radical cystectomy as primary therapy for T4 bladder cancer

Authors: Udo Nagele, Aristotelis G. Anastasiadis, Axel S. Merseburger, Stefan Corvin, Jörg Hennenlotter, Melanie Adam, Karl-Dietrich Sievert, Arnulf Stenzl, Markus A. Kuczyk

Published in: World Journal of Urology | Issue 4/2007

Login to get access

Abstract

Treatment of T4 bladder cancer patients remains a clinical challenge. Conservative management is often insufficient regarding local control, neoadjuvant chemotherapy delays definite treatment while leading to increased therapy-associated morbidity and mortality during the course of the disease. Primary cystectomy has also been reported to be associated with a high complication rate and unsatisfactory clinical efficacy. Herein, we report postoperative outcome, including therapy-related complications, in 20 T4 bladder cancer patients subjected to primary cystectomy. Twenty patients underwent radical cystectomy for T4 bladder cancer. At the time of surgery, 8 patients had regional lymph node metastases. The median postoperative follow-up was 13 months for the whole group. Mean duration of postoperative hospitalization was 19 days. Ten patients received no intra- or postoperative blood transfusions, whereas an average number of 3 blood units were administered in the remaining cases. Major therapy-associated complications were paresthesia affecting the lower extremities (n = 3) as well as insignificant pulmonary embolism, enterocutaneous fistulation and acute renal failure in one patient, respectively. At the time of data evaluation, 11 patients were still alive after a follow-up of 20 months. Four patients ≥70 years at the time of cystectomy were still alive after 11, 22 and 31 months following surgery, respectively. The current data demonstrate primary cystectomy for T4 bladder cancer as a technically feasible approach that is associated with a tolerable therapy-related morbidity. Additionally, satisfying clinical outcome is observed even in a substantial number of elderly patients.
Literature
1.
go back to reference Skinner DG, Stein JP, Lieskovsky G, Skinner EC, Boyd SD, Figueroa A et al (1998) 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 33(Suppl 4):25–26PubMedCrossRef Skinner DG, Stein JP, Lieskovsky G, Skinner EC, Boyd SD, Figueroa A et al (1998) 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 33(Suppl 4):25–26PubMedCrossRef
2.
go back to reference Figueroa AJ, Stein JP, Dickinson M, Skinner EC, Thangathurai D, Mikhail MS et al (1998) Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer 83(1):141–147PubMedCrossRef Figueroa AJ, Stein JP, Dickinson M, Skinner EC, Thangathurai D, Mikhail MS et al (1998) Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer 83(1):141–147PubMedCrossRef
3.
go back to reference Zebic N, Weinknecht S, Kroepfl D (2005) Radical cystectomy in patients aged > or = 75 years: an updated review of patients treated with curative and palliative intent. BJU Int 95(9):1211–1214PubMedCrossRef Zebic N, Weinknecht S, Kroepfl D (2005) Radical cystectomy in patients aged > or = 75 years: an updated review of patients treated with curative and palliative intent. BJU Int 95(9):1211–1214PubMedCrossRef
4.
go back to reference Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20(14):3061–3071PubMedCrossRef Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20(14):3061–3071PubMedCrossRef
5.
go back to reference Dunst J, Diestelhorst A, Kuhn R, Muller AC, Scholz HJ, Fornara P (2005) Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol 181(10):632–637PubMedCrossRef Dunst J, Diestelhorst A, Kuhn R, Muller AC, Scholz HJ, Fornara P (2005) Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol 181(10):632–637PubMedCrossRef
6.
go back to reference Arias F, Dominguez MA, Martinez E, Illarramendi JJ, Miquelez S, Pascual I et al (2000) Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 47(2):373–378PubMedCrossRef Arias F, Dominguez MA, Martinez E, Illarramendi JJ, Miquelez S, Pascual I et al (2000) Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 47(2):373–378PubMedCrossRef
7.
go back to reference Chen WC, Liaw CC, Chuang CK, Chen MF, Chen CS, Lin PY, et al. (2003) Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 56(3):726–733PubMedCrossRef Chen WC, Liaw CC, Chuang CK, Chen MF, Chen CS, Lin PY, et al. (2003) Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 56(3):726–733PubMedCrossRef
8.
go back to reference Tekin A, Aki FT, Ozen H (2001) Radical cystectomy versus alternative treatments for muscle-confined bladder cancer. Int Urol Nephrol 33(2):357–362PubMedCrossRef Tekin A, Aki FT, Ozen H (2001) Radical cystectomy versus alternative treatments for muscle-confined bladder cancer. Int Urol Nephrol 33(2):357–362PubMedCrossRef
9.
go back to reference Wilson JR, Urwin GH, Stower MJ (2005) The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87(1):21–24PubMedCrossRef Wilson JR, Urwin GH, Stower MJ (2005) The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl 87(1):21–24PubMedCrossRef
10.
go back to reference Lodde M, Palermo S, Comploj E, Signorello D, Mian C, Lusuardi L et al (2005) Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur Urol 47(6):773–778; discussion 778–9 Lodde M, Palermo S, Comploj E, Signorello D, Mian C, Lusuardi L et al (2005) Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur Urol 47(6):773–778; discussion 778–9
11.
go back to reference George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C et al (2004) Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 64(3):488–493PubMedCrossRef George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C et al (2004) Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 64(3):488–493PubMedCrossRef
12.
go back to reference Douglas RM, Kaufman DS, Zietman AL, Althausen AF, Heney NM, Shipley WU (1996) Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol 23(5):614–620PubMed Douglas RM, Kaufman DS, Zietman AL, Althausen AF, Heney NM, Shipley WU (1996) Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol 23(5):614–620PubMed
13.
go back to reference Mantadakis E, Panagiotidis C, Delakas D, Samonis G (2003) Symptomatic relief of patients with advanced bladder carcinoma after regional intra-arterial chemotherapy. Anticancer Res 23(6D):5143–5147PubMed Mantadakis E, Panagiotidis C, Delakas D, Samonis G (2003) Symptomatic relief of patients with advanced bladder carcinoma after regional intra-arterial chemotherapy. Anticancer Res 23(6D):5143–5147PubMed
14.
go back to reference Hussain MH, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M et al (2001) Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol 165(1):56–60; discussion 60–1 Hussain MH, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M et al (2001) Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol 165(1):56–60; discussion 60–1
15.
go back to reference Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866PubMedCrossRef Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP, Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866PubMedCrossRef
16.
go back to reference Hautmann RE (1998) Complications and results after cystectomy in male and female patients with locally invasive bladder cancer. Eur Urol 33(Suppl 4):23–24PubMedCrossRef Hautmann RE (1998) Complications and results after cystectomy in male and female patients with locally invasive bladder cancer. Eur Urol 33(Suppl 4):23–24PubMedCrossRef
17.
go back to reference Teramukai S, Nishiyama H, Matsui Y, Ogawa O, Fukushima M (2006) Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res 12(1):139–143PubMedCrossRef Teramukai S, Nishiyama H, Matsui Y, Ogawa O, Fukushima M (2006) Evaluation for surrogacy of end points by using data from observational studies: tumor downstaging for evaluating neoadjuvant chemotherapy in invasive bladder cancer. Clin Cancer Res 12(1):139–143PubMedCrossRef
18.
go back to reference Cam K, Yildirim A, Ozveri H, Turkeri L, Akdas A (2002) The efficacy of neoadjuvant chemotherapy in invasive bladder cancer. Int Urol Nephrol 33(1):49–52PubMedCrossRef Cam K, Yildirim A, Ozveri H, Turkeri L, Akdas A (2002) The efficacy of neoadjuvant chemotherapy in invasive bladder cancer. Int Urol Nephrol 33(1):49–52PubMedCrossRef
19.
go back to reference Nieuwenhuijzen JA, Horenblas S, Meinhardt W, van Tinteren H, Moonen LM (2004) Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int 94(6):793–797PubMedCrossRef Nieuwenhuijzen JA, Horenblas S, Meinhardt W, van Tinteren H, Moonen LM (2004) Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int 94(6):793–797PubMedCrossRef
Metadata
Title
The rationale for radical cystectomy as primary therapy for T4 bladder cancer
Authors
Udo Nagele
Aristotelis G. Anastasiadis
Axel S. Merseburger
Stefan Corvin
Jörg Hennenlotter
Melanie Adam
Karl-Dietrich Sievert
Arnulf Stenzl
Markus A. Kuczyk
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
World Journal of Urology / Issue 4/2007
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-007-0172-9

Other articles of this Issue 4/2007

World Journal of Urology 4/2007 Go to the issue